Introduction
============

Bladder cancer is a malignancy of the bladder mucosa; it is the most common malignancy of the urinary system. Its incidence ranks top among all urogenital tumors in China, and ranks second in Western countries only to prostate cancer ([@b1-ol-0-0-6471]--[@b5-ol-0-0-6471]). Bladder urothelial carcinoma is diagnosed mainly via cystoscopy ([@b6-ol-0-0-6471],[@b7-ol-0-0-6471]).

miRNAs are a class of evolutionarily conserved non-coding small molecule RNAs that function by regulating gene expression at the translational level; the specific biological targets of most miRNAs remain to be discovered ([@b8-ol-0-0-6471],[@b9-ol-0-0-6471]). miRNAs have been found to regulate cell growth and tissue differentiation, and thus play roles during development and can be involved in the establishment of diseases such as cancer ([@b10-ol-0-0-6471]). A series of studies have shown that microRNAs play roles in cell growth and apoptosis, hemocytes differentiation, homeobox gene regulation, neuronal polarity, insulin secretion, cerebral morphogenesis, cardiac development and postembryonic development ([@b11-ol-0-0-6471]--[@b14-ol-0-0-6471]). Active research focuses on the association between miRNAs and different tumor development.

This study was designed in order to analyze the information contained in The Cancer Genome Atlas (TCGA) for bladder urothelial carcinoma patients, so as to identify independent prognostic miRNAs that should be useful as reference markers for the diagnosis of the cancer.

Materials and methods
=====================

The miRNA data for bladder urothelial carcinoma patients were downloaded from TCGA in the USA. The data involved cases from 1991 to 2013. Overall the tissue specimen data of 418 patients diagnosed with bladder urothelial carcinoma as well as the data for 19 cases of para-carcinoma tissue specimens were obtained from TCGA. To study the association between miRNA expression and clinical features in patients with bladder urothelial carcinoma in an accurate manner, we selected the patient data according to the following criteria: The age of the patient was available, the survival time was longer than 1 month and pathology had confirmed the diagnosis of bladder urothelial carcinoma. After exclusion, a total of 399 cases of bladder urothelial carcinoma and 19 cases with para-carcinoma tissue specimens were included in this study. The available clinical features included age, sex, race, the American Joint Committee on Cancer (AJCC) TNM staging system classification, the survival time and the survival status.

The miRNA expression data for the samples of 399 bladder urothelial carcinoma patients and 19 para-carcinoma specimens were included in the analysis, and a total of 1,581 miRNAs were detected in tissue specimens by using the Illumina HiSeq platform and the Illumina Genome Analyzer platform. To screen out the differentially expressed miRNAs, we set the screening criteria as log fold-change \>2 and the associated P\<0.01 miRNAs that were upregulated and downregulated in the tissue specimens of bladder urothelial carcinoma patients were screened out, and the expression of miRNA was normalized.

In addition, we transformed the miRNA expression levels into log2, and screened out the miRNAs and clinical features that were associated with the survival of bladder urothelial carcinoma using the univariate Cox proportional hazards regression. Then, we used the multivariate Cox proportional hazards regression to screen out the independent prognostic factors of bladder urothelial carcinoma. Furthermore, we performed a Kaplan-Meier (KM) survival curve analysis on the independent prognostic miRNAs for bladder urothelial carcinoma, divided the miRNA levels into high-expression and low-expression groups with the median as the cut-off point, and processed data using the survival package of the R software, version 2.14.1 (R development Core Team, Vienna Austria, 2009) ([@b15-ol-0-0-6471]).

TargetScan was used for target prediction on the independent prognostic miRNAs for bladder urothelial carcinoma. After excluding repeated target genes, cytoscape was used performing a GO enrichment analysis on target genes (p\<0.05) to screen out ten functions with the closest relationship to target genes. Finally, KOBAS was used for KEGG pathway enrichment analysis on the target genes to screen out ten pathways with the closest association to target genes.

Results
=======

The data from a total of 399 patients with bladder urothelial carcinoma were included in the analysis. The data for the expression of 1,581 miRNAs and a variety of clinical features can be seen in [Table I](#tI-ol-0-0-6471){ref-type="table"}. In addition, we found the up and downregulated miRNAs in bladder urothelial carcinoma. Among them, the ten most upregulated miRNAs were hsa-mir-210, hsa-mir-96, hsa-mir-18a, hsa-mir-183, hsa-mir-130b, hsa-mir-141, hsa-mir-33a, hsa-mir-345, hsa-mir-182 and hsa-mir-301a ([Table II](#tII-ol-0-0-6471){ref-type="table"}), whereas, the most downregulated ones were hsa-mir-143, hsa-mir-1298, hsa-mir-139, hsa-mir-1-2, hsa-mir-195, hsa-mir-1-1, hsa-mir-133a-1, hsa-mir-30a, hsa-mir-133a-2 and hsa-mir-133b ([Table III](#tIII-ol-0-0-6471){ref-type="table"}).

The univariate Cox proportional risk regression shown in [Table I](#tI-ol-0-0-6471){ref-type="table"} demonstrates the clinical features of pathology N stage (p=1.01E-07), pathology M stage (p=0.0002), pathology T stage (p=0.0005) and patient\'s age (p=0.007) were all closely associated with the survival length for bladder urothelial carcinoma. As for the miRNAs, related to the bladder urothelial carcinoma survival, a total of 19 miRNAs stood out, of which the three most closely related ones were hsa-mir-99a (p=0.0001), hsa-let-7c (p=0.0004) and hsa-mir-100 (p=0.0005).

Next, a multivariate Cox proportional risk regression showed the pathology N stage (p=0.00007), hsa-mir-518b (p=0.02), the patient\'s age (p=0.03), hsa-mir-192 (p=0.04) and hsa-mir-7705 (p=0.04) were all independent prognostic factors for bladder urothelial carcinoma ([Table IV](#tIV-ol-0-0-6471){ref-type="table"}). We performed KM survival curve analyses on the three independent prognostic miRNAs. As shown in [Figs. 1](#f1-ol-0-0-6471){ref-type="fig"}--[3](#f3-ol-0-0-6471){ref-type="fig"}, there were significant differences in the survival time between the high- and low-expression levels of hsa-mir-7705 and hsa-mir-192, while the survival time between the high- and low-expression levels of hsa-mir-518b did not differ significantly.

Finally, we used TargetScan to predict the target genes of three independent prognostic miRNAs, and then used Cytoscape to perform a GO enrichment analysis on all target genes. As shown in [Table V](#tV-ol-0-0-6471){ref-type="table"}, the three most significant functions found were transcription regulator activity, regulation of transcription from RNA polymerase II promoter and regulation of transcription. The KEGG pathway analysis revealed that the most closely related pathway was Cytokine-cytokine receptor interaction ([Table VI](#tVI-ol-0-0-6471){ref-type="table"}).

Discussion
==========

Bladder cancer is the most common malignancy of the urinary system. Studies have found that miRNAs can regulate the expression of tens to hundreds of genes, and that miRNAs play a hub role in tumorigenesis and progression as regulatory molecules in the processes of gene expression and protein translation ([@b16-ol-0-0-6471],[@b17-ol-0-0-6471]). Although these endogenous miRNAs only account for 2% of the total human transcripts, they regulate the expression of \>30% of the genes in the whole human genome. Therefore, research on the function of miRNAs and their association to the development of cancer is of great significance. This study identified independent prognostic factors of bladder urothelial carcinoma by studying the expression data of miRNAs.

We extracted the miRNA expression data of bladder urothelial carcinoma from the free and open TCGA. After screening, we listed the ten most significantly upregulated and downregulated miRNAs in the specimens, of which the most pronouncedly upregulated ones were hsa-mir-210, hsa-mir-96 and hsa-mir-18a. The level of hsa-miR-210 has been associated with hypoxia in head and neck tumors and other indicators, and a high hsa-miR-210 expression is closely related to disease recurrence and overall survival time ([@b18-ol-0-0-6471]). In addition, another study showed that hsa-miR-210 is an independent prognostic marker for breast cancer, and that hsa-miR-210 overexpression is induced by hypoxia in a HIF-1α- and VHL-dependent manner ([@b19-ol-0-0-6471]). Then, the miRNA hsa-miR-96 can upregulate the levels of IRS1 and MAP4K1 to affect bladder cancer cell growth and has been signaled as a promising diagnostic marker for human bladder urothelial carcinomas ([@b20-ol-0-0-6471]). Interestingly, hsa-mir-18a has also been shown to be involved in many cancer processes. A study demonstrated that hsa-mir-18a was able to prevent estrogen receptor-α expression and promote hepatoma cell proliferation ([@b21-ol-0-0-6471]).

In addition, we screened out the three best independent prognostic miRNAs for bladder urothelial carcinoma by constructing a multivariate Cox regression model, and obtained hsa-mir-518b (p=0.02), hsa-mir-192 (p=0.04) and hsa-mir-7705 (p=0.04). Furthermore, by plotting the KM survival curve, we found that the survival time of patients expressing high hsa-mir-7705 and hsa-mir-192 levels were significantly shorter than those of patients expressing low levels. In addition, both hsa-mir-7705 and hsa-mir-192 were upregulated in the bladder urothelial carcinoma samples. A study in mice showed that together with elevated transforming growth factor-β (TGF-β) and Col1a2 levels, the levels of miR-192 are significantly higher in the glomeruli of diabetic mice when compared to the levels in non-diabetic controls, these finding suggest that miRNAs in the kidney play a role downregulating E-box repressors to control the TGF-β-induced Col1a2 expression ([@b22-ol-0-0-6471]).

Finally, we predicted target genes for the three independent prognostic miRNAs, and then subjected those target genes to GO enrichment analysis using Cytoscape. The transcription regulator activity was the most closely associated enrichment area, while the other findings included transcription from RNA polymerase II promoter and regulation of transcription. The KEGG pathway results pointed to three associated pathways including Cytokine-cytokine receptor interactions, TGF-β, and PI3K-Akt signaling pathways. According to Kaminska *et al* TGF-β signaling inhibitors may be promising novel, potential antitumor therapeutics as they decrease glioma viability and invasion in animal models ([@b23-ol-0-0-6471]). In addition, other researchers have shown possible initiation of pathological changes in osteoarthritis by high concentrations of active TGF-β1 in subchondral bone, and a potential approach for managing this disease may be to suppress TGF-β1 ([@b24-ol-0-0-6471]). Finally, the PI3K-Akt signaling pathway has also been studied, and it is thought that phosphoinositide 3-kinases (PI3Ks) are involved in a variety of tumor processes ([@b25-ol-0-0-6471]).

Even though this study identified three independent prognostic miRNAs, we are aware of the study\'s limitations. Firstly, all 399 cases of bladder urothelial carcinoma were from a single database (TCGA), so verification with data from another database is needed. On the same line, 399 cases are a rather small group size; so larger sample verification is needed. Finally, PCR validation assays will definitely enhance the reliability of our findings.

In conclusion, our approach was successful in identifying hsa-mir-7705, hsa-mir-192 and hsa-mir-518b as independent prognostic factors for bladder urothelial carcinoma.
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###### 

Clinical features of bladder urothelial carcinoma.

  Characteristics               Data (TCGA)
  ----------------------------- -------------
  Age                           
    ≤65                         160
    \>65                        239
  Sex                           
    Female                      105
    Male                        294
  Race                          
    White                       318
    Asian                       40
    Black or African American   23
    NA                          18
  Pathology stage               
    Stage I                     2
    Stage II                    125
    Stage III                   137
    Stage IV                    133
    NA                          2
  T stage                       
    T0                          1
    T1                          3
    T2                          114
    T3                          191
    T4                          58
    TX                          1
    NA                          31
  N stage                       
    N0                          229
    N1                          46
    N2                          76
    N3                          7
    NA                          5
    NX                          36
  M stage                       
    M0                          188
    M1                          10
    MA                          198
    MX                          3
  Survival state                
    Survive                     223
    Dead                        176

TCGA, The Cancer Genome Atlas.

###### 

The top ten miRNA of upregulated expression.

  miRNA          logFC         logCPM        P-value    FDR
  -------------- ------------- ------------- ---------- ----------
  hsa-mir-210    4.803108853   9.8642203     3.45E-18   3.63E-16
  hsa-mir-96     3.410662815   5.143223988   1.15E-16   1.07E-14
  hsa-mir-18a    2.988898835   5.68100551    6.61E-16   5.50E-14
  hsa-mir-183    2.943927749   13.56270017   2.06E-14   1.25E-12
  hsa-mir-130b   2.303867052   5.74901106    2.72E-14   1.59E-12
  hsa-mir-141    2.494450708   11.09284497   1.42E-11   5.49E-10
  hsa-mir-33a    2.22270633    4.907692995   7.44E-11   2.67E-09
  hsa-mir-345    2.673695186   4.694451091   1.23E-10   4.23E-09
  hsa-mir-182    2.254097092   14.41365672   1.34E-10   4.49E-09
  hsa-mir-301a   2.088008339   4.476181049   1.76E-10   5.79E-09

###### 

The top ten miRNA of downregulated expression.

  miRNA            logFC          logCPM        P-value    FDR
  ---------------- -------------- ------------- ---------- ----------
  hsa-mir-143      −3.599914903   17.8945552    3.72E-46   5.88E-43
  hsa-mir-1298     −4.526050745   1.187271104   1.13E-39   8.92E-37
  hsa-mir-139      −2.621941214   6.101969894   9.29E-39   4.89E-36
  hsa-mir-1-2      −3.736158674   5.508819647   4.22E-34   1.67E-31
  hsa-mir-195      −2.432143312   4.989973255   6.44E-33   2.04E-30
  hsa-mir-1-1      −3.693697839   5.417492946   1.41E-32   3.73E-30
  hsa-mir-133a-1   −3.558543939   5.92141089    2.24E-28   5.06E-26
  hsa-mir-30a      −2.228925868   13.94817286   6.07E-27   1.20E-24
  hsa-mir-133a-2   −3.515469057   5.736507      2.23E-26   3.92E-24
  hsa-mir-133b     −3.88838679    4.46304315    3.14E-26   4.97E-24

###### 

Univariate and multivariate analyses.

                      Univariate analysis   Multivariate analysis           
  ------------------- --------------------- ----------------------- ------- ---------
  Pathology N stage   0.87                  0.0000001               0.78    0.00007
  hsa-mir-518b        0.08                  0.04                    0.1     0.02
  Age                 0.49                  0.007                   0.42    0.03
  hsa-mir-192         −0.17                 0.01                    −0.17   0.04
  hsa-mir-7705        −0.22                 0.04                    −0.24   0.04

CI, confidence interval.

###### 

The analysis of GO enrichment.

  GO-ID   P-value    Corr P-value   Description
  ------- ---------- -------------- -------------------------------------------------------------------------------------
  30528   1.28E-10   1.86E-07       Transcription regulator activity
  6357    4.58E-07   2.29E-04       Regulation of transcription from RNA polymerase II promoter
  45449   7.35E-07   2.29E-04       Regulation of transcription
  16564   7.93E-07   2.29E-04       Transcription repressor activity
  3676    8.48E-07   2.29E-04       Nucleic acid binding
  19219   9.42E-07   2.29E-04       Regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
  51171   1.18E-06   2.45E-04       Regulation of nitrogen compound metabolic process
  6355    1.92E-06   3.49E-04       Regulation of transcription, DNA-dependent
  5634    2.71E-06   4.39E-04       Nucleus
  51252   3.24E-06   4.62E-04       Regulation of RNA metabolic process

GO, Gene Ontology.

###### 

The analysis of KEGG enrichment.

  Term                                      Database       ID         P-value       Corrected P-value
  ----------------------------------------- -------------- ---------- ------------- -------------------
  Cytokine-cytokine receptor interaction    KEGG PATHWAY   hsa04060   0.000784246   0.025901739
  TGF-β signaling pathway                   KEGG PATHWAY   hsa04350   0.001564908   0.025901739
  PI3K-Akt signaling pathway                KEGG PATHWAY   hsa04151   0.001619992   0.025901739
  mRNA surveillance pathway                 KEGG PATHWAY   hsa03015   0.001865223   0.025901739
  NF-κB signaling pathway                   KEGG PATHWAY   hsa04064   0.00190454    0.025901739
  Sphingolipid signaling pathway            KEGG PATHWAY   hsa04071   0.003163201   0.035849606
  Apoptosis                                 KEGG PATHWAY   hsa04210   0.004187233   0.040675974
  Transcriptional misregulation in cancer   KEGG PATHWAY   hsa05202   0.00677533    0.049549952
  Herpes simplex infection                  KEGG PATHWAY   hsa05168   0.007212651   0.049549952
  Chemokine signaling pathway               KEGG PATHWAY   hsa04062   0.007286758   0.049549952

KEGG, Kyoto Encyclopedia of Genes and Genomes; TGF-β, transforming growth factor-β; PI3K, phosphoinositide 3-kinase; NF-κB, nuclear factor-κB.
